Pfizer (PFE) recently announced positive results from its Phase 3 EV-303 clinical trial in collaboration with Astellas Pharma ...

The FDA accepted vepdegestrant’s new drug application for ER+/HER2–, ESR1-mutated advanced breast cancer with a June 5, 2026, ...

Study participants were randomly assigned to receive either oral vepdegestrant (n=313) or intramuscular fulvestrant (n=311). The primary endpoint was progression free survival (PFS) among all patients ...

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...

US FDA accepts Arvinas’ NDA for vepdegestrant to treat ESR1m, ER+/HER2- advanced breast cancer: New Haven, Connecticut Monday, August 11, 2025, 17:00 Hrs [IST] Arvinas, Inc., a ...

Arvinas, in collaboration with Pfizer, has announced new drug application (NDA) acceptance for vepdegestrant from the US Food ...

Investors should continue to retain this Zacks Rank #3 (Hold) stock in their portfolio as it appears to have significant ...

Shares of Arvinas Inc. (ARVN) fell 4% on Thursday as Wall Street sounded contradicting opinions on the future of its ...

Newcomers will not only be plugging into UPS while its forward-looking yield stands at 7.4%, but while the stock's priced ...

If vepdegestrant can consistently demonstrate superior efficacy and safety in ESR1 mutant patients compared to other treatments, it could become the standard of care for this subset of breast cancer ...

Vepdegestrant: A Promising Asset with Challenges Vepdegestrant, Arvinas’s lead drug candidate, has shown encouraging results in recent clinical trials.